GSK Lowers Full-Year Vaccine Guidance After Disappointing Q2 Sales, CDC RSV Guidelines

Systemic administrative and policy challenges, including updated CDC guidelines regarding the use of RSV shots in seniors, have forced GSK to lower its 2024 outlook for its vaccines business.